Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
For follow-up milk feeding from 6 months onwards [when breast milk is not available or has to be supple-mented], as a complement to weaning foods continue with use NAN H.A.2 as a follow-up to NAN H.A.1.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Adverse reactions vary by agent. Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes). Report suspected ADRs via national pharmacovigilance channels.
Store as labelled. Keep out of reach of children.